| antineoplastic | Q2853144 |
| Q7089373 | (-)-homoharringtonine |
| Q204036 | (E)-cinnamaldehyde |
| Q5150954 | (R)-(-)-combretastatin |
| Q410215 | (R)-amygdalin |
| Q416800 | (±)-carvone |
| Q27155328 | 10-hydroxycamptothecin |
| Q5382492 | Epicatechin gallate |
| Q7840974 | Ribosome-inactivating protein alpha-trichosanthin |
| Q15633955 | acronine |
| Q100138042 | asimicin |
| Q384111 | betulinic acid |
| Q419964 | camptothecin |
| Q15410888 | cepharanthine |
| Q5175227 | costunolide |
| Q16959658 | demecolcine |
| Q418817 | etoposide |
| Q5150956 | fosbretabulin |
| Q27077807 | ginsenoside Rg3 |
| Q27106735 | glaucarubin |
| Q5597007 | grape seed extract |
| Q387505 | helenalin |
| Q5896650 | honokiol |
| Q412197 | irinotecan |
| Q739601 | lapachol |
| Q6720157 | maytansine |
| Q905397 | mezerein |
| Q27293498 | namitecan |
| Q423762 | paclitaxel |
| Q2550553 | plumbagin |
| Q421193 | podofilox |
| Q22075831 | podophyllin |
| Q407329 | resveratrol |
| Q27108154 | retrorsine |
| Q27291219 | saikosaponin d |
| Q110589811 | schizophyllan |
| Q2083871 | senecionine |
| Q27247588 | tanshinone I |
| Q7706612 | tetrandrine |
| Q415324 | tridolgosir |
| Q416260 | ursolic acid |
| Q411426 | verbascoside |
| Q282629 | vinblastine |
| Q408977 | vincristine |
| Q416660 | vindesine |
| Q420532 | vinorelbine |
| Q27108568 | xanthatin |
| Q2705171 | β-thujaplicin |
| Q113924617 | "Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients" |
| Q113922682 | A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC |
| Q113928932 | A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma |
| Q113898609 | A Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies |
| Q113944182 | A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer |
| Q113939504 | A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma |
| Q113890525 | A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) |
| Q113888193 | A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy |
| Q113921095 | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) |
| Q113919947 | A PK Study of Oraxol in Breast Cancer Patients |
| Q113910001 | A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients |
| Q113892273 | A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer |
| Q113910958 | A Phase I/II Study of Diffuse Large B-cell Lymphoma |
| Q113897403 | A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer |
| Q113938175 | A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer |
| Q113926734 | A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors |
| Q113918499 | A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer |
| Q113920163 | A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome. |
| Q113916469 | A Prospective Randomized Controlled Study of Radiotherapy and the Concurrent Three-week and Single-week TP Chemotherapy for Advanced Cervical Squamous Cell Carcinoma and the Correlation Between HPV Classification and Sensitivity. |
| Q113890595 | A Prospective Study Comparing Two Radiotherapy Dose/Fraction and Omitting CTVs of the Primary Tumor in Limited SCLC |
| Q113911124 | A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma |
| Q113916197 | A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metas |
| Q113931143 | A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
| Q113945114 | A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer |
| Q113896401 | A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer |
| Q113918916 | A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer |
| Q113929554 | A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer |
| Q113896888 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors |
| Q113895704 | A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma |
| Q113887792 | A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma. |
| Q113922466 | A Study of Atezolizumab Compared With Platinum Doublet Chemotherapy for PD-L1 Highly Expressed, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer |
| Q113923208 | A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer |
| Q113916310 | A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors |
| Q113889115 | A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients |
| Q113913918 | A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC) |
| Q113918128 | A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC |
| Q113885185 | A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma |
| Q113939736 | A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor |
| Q113945394 | A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON) |
| Q113944448 | A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors |
| Q113936540 | A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
| Q113936287 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) |
| Q113910962 | A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy |
| Q113888340 | A Study of Targeted Agents With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer |
| Q113897032 | A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT |
| Q113896913 | A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positi |
| Q113941371 | A Study to Evaluate Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment |
| Q113917829 | A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer |
| Q113888870 | A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors |
| Q113941835 | A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) |
| Q113938434 | A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC) |
| Q113920009 | A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC |
| Q113928142 | A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients |
| Q113893013 | A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC |
| Q113896968 | A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer |
| Q113933359 | ACOART SCB BIF: Treatment of Coronary Bifurcation Lesion by Sirolimus Coated Balloon vs Paclitaxel Coated Balloon |
| Q113894366 | AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer |
| Q113940610 | AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer |
| Q113943920 | AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC |
| Q113927347 | AN0025 and Chemoradiotherapy Combination in Esophageal Cancer |
| Q113889826 | AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer |
| Q113919175 | ATEMPT 2.0: Adjuvant T-DM1 vs TH |
| Q113892311 | Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) |
| Q113942053 | Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study |
| Q113922245 | Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC |
| Q113913872 | Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor |
| Q113920658 | Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer |
| Q113924615 | Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma. |
| Q113944769 | Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer |
| Q113894676 | Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer |
| Q113890477 | Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer |
| Q113942661 | An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese |
| Q113918081 | An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo) |
| Q113941637 | Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer |
| Q113897020 | Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer |
| Q113897398 | Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma |
| Q113920310 | Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer |
| Q113944319 | Atezolizumab Plus CArboplatin Plus Nab-paclitaxel |
| Q113944934 | Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer |
| Q113939008 | Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors |
| Q113897332 | Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC |
| Q113892579 | Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046) |
| Q113938808 | Biomarker Discovery in Patients With Advanced Biliary Tract Cancer |
| Q113889976 | Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL |
| Q113917252 | Brentuximab Vedotin in Early Stage Hodgkin Lymphoma |
| Q113895306 | CDK4/6 Tumor, Abemaciclib, Paclitaxel |
| Q113939502 | Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer |
| Q113892614 | Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer |
| Q113936183 | Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer |
| Q113939130 | Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC |
| Q113891023 | Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC |
| Q113887624 | Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). |
| Q113910562 | Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck |
| Q113939339 | Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer |
| Q113921582 | Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer |
| Q113943866 | ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer |
| Q113887833 | Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer |
| Q113944237 | Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma |
| Q113909475 | Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer |
| Q113941074 | Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma |
| Q113926321 | Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma |
| Q113922485 | Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer |
| Q113891145 | Clinical Study of PD-1 Antibody (BGB-A317) Plus Chemotherapy (Cisplatin and Etoposide) for Limited Stage Small Cell Lung Cancer |
| Q113894657 | Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients. |
| Q113898273 | Combination Therapy for First Line Treatment of Advanced Cervical Cancer |
| Q113945126 | Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations |
| Q113898626 | Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients |
| Q113918283 | Comparative Clinical Study of Drug-coating Balloon Strategy and Drug-eluting Stent Strategy |
| Q113911915 | Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Chinese Patients With Coronary ISR |
| Q113941774 | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy |
| Q113912061 | Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents |
| Q113937895 | Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer |
| Q113920334 | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer |
| Q113933298 | Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study |
| Q113938276 | DDP ip Combined With AG in PDAC With Peritoneal Metastasis |
| Q113918375 | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia |
| Q113938651 | De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade |
| Q113895716 | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma |
| Q113944767 | Donafenib for Recurrent Cervical Cancer |
| Q113891034 | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults |
| Q113915597 | Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer |
| Q113923335 | Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES) |
| Q113898720 | Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC |
| Q113941745 | Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial |
| Q113944512 | Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium |
| Q113939491 | Effect of Silibinin(A) as a Potential Anti-obesity Agent |
| Q113942918 | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076) |
| Q113913932 | Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer |
| Q113936874 | Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer |
| Q113889261 | Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer |
| Q113894705 | Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer. |
| Q113891923 | Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients |
| Q113912747 | Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer |
| Q113932262 | Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis |
| Q113892192 | Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer |
| Q113912037 | Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in NACT for Locally Advanced Cervical Cancer |
| Q113922418 | Endometrial Cancer Patientes MMR Deficient Comparing Chimiotherapy vs Dostarlimab in First Line |
| Q113941228 | Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer |
| Q113921156 | Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study |
| Q113938851 | Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma |
| Q113895059 | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma |
| Q113911051 | First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients |
| Q113915553 | First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers. |
| Q113889654 | First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients |
| Q113909575 | Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer |
| Q113918753 | Food Effect on Pharmacokinetics and SafEty of DHP107 (Liporaxel®) FEEL Study |
| Q113923113 | GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma |
| Q113944343 | GVM±R in Patients With Relapsed or Refractory Aggressive NHL |
| Q113894654 | GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab |
| Q113909426 | Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer |
| Q113911030 | Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis |
| Q113928365 | Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial |
| Q113893888 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer |
| Q113938772 | Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA) |
| Q113917444 | Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC). |
| Q113941529 | Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial |
| Q113888371 | Immunotherapy in Lung Cancer: Treatment After IO Cessation. |
| Q113887134 | Inductive Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients |
| Q113945747 | Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer |
| Q113938006 | Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis |
| Q113924524 | Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Ovarian, Colorectal, or Appendiceal Cancer |
| Q113897168 | Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer |
| Q113891942 | Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL |
| Q113917734 | Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy |
| Q113933223 | Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma |
| Q113943196 | Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies |
| Q113896057 | Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models |
| Q113913964 | MicroRNA Profiles in Triple Negative Breast Cancer |
| Q113898507 | Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. |
| Q113898049 | Nab-PTX, Ifosfamide and Cisplatin in the Treatment of Pediatric Extracranial Germ Cell Tumor. |
| Q113910648 | Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation Study |
| Q113913823 | Nab-paclitaxel Combined With Bevacizumab in the Treatment of Metastatic Neuroendocrine Carcinoma |
| Q113920633 | Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer |
| Q113943706 | Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer |
| Q113914211 | Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC |
| Q113892133 | Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC |
| Q113926533 | Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer |
| Q113895050 | Neoadjuvant Immunotherapy to ESCC |
| Q113924322 | Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC |
| Q113918684 | Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms |
| Q113915460 | Neoadjuvant Treatment Modalities in Esophageal Cancer |
| Q113887766 | Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE） |
| Q113892199 | New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy |
| Q113888883 | New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study |
| Q113909745 | Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy |
| Q113919044 | Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 |
| Q113887226 | Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer |
| Q113888788 | PAXG Out in the Country |
| Q113898197 | PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML |
| Q113896988 | PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL |
| Q113918689 | POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer |
| Q113913826 | Paclitaxel (Albumin-bound) Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinoma |
| Q113939939 | Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions |
| Q113892170 | Paclitaxel-coated Balloon for Treatment of De-novo Non-complex Coronary Artery Lesions |
| Q113887231 | Pancreatic Adenocarcinoma Neoadjuvant Combination Chemotherapy and Stereotactic Body Radiation Therapy Before Surgery |
| Q113915638 | Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy. |
| Q113927781 | Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL |
| Q113891617 | Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer |
| Q113888520 | Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell Lymphoma |
| Q113918870 | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study |
| Q113940968 | Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma |
| Q113924331 | Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer |
| Q113944501 | Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC |
| Q113939310 | Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| Q113894054 | Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer With HRR Mutation and MSS |
| Q113937848 | Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008) |
| Q113924841 | Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma |
| Q113911754 | Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043) |
| Q113911806 | Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma |
| Q113915065 | Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC |
| Q113898429 | Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) |
| Q113943042 | Phase I Study of the Combination of Irinotecan and POF (POFI) |
| Q113898671 | Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17) |
| Q113892411 | Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer |
| Q113895964 | Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas |
| Q113914807 | Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline |
| Q113918865 | Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC |
| Q113940595 | Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC |
| Q113921426 | Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer |
| Q113942468 | Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases |
| Q113894232 | Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer |
| Q113918046 | Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer |
| Q113919367 | Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer |
| Q113926570 | Pyrotinib in Combination With Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: A Phase II Trial |
| Q113914317 | R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study |
| Q113944453 | RAGE Inhibition to Decrease Cancer Related Cognitive Decline (CRCD) in Women With Non-metastatic Breast Cancer |
| Q113936505 | Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC |
| Q113894683 | Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer |
| Q113896444 | Real-World Safety Analysis of Paclitaxel Devices Used for the Treatment of Peripheral Arterial Disease |
| Q113918929 | Real-world Data (RWD) of Ramucirumab Plus Paclitaxel |
| Q113942364 | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer |
| Q61894464 | Resveratrol and First-degree Relatives of Type 2 Diabetic Patients |
| Q113929023 | Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype |
| Q113918095 | Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study |
| Q113920465 | Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study |
| Q113945347 | S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC |
| Q113924516 | SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer |
| Q113925516 | SMMART Adaptive Clinical Treatment (ACT) Trial |
| Q113910556 | Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel |
| Q113924319 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma |
| Q113941624 | Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer |
| Q113920806 | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) |
| Q113892833 | Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi |
| Q113920178 | Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours |
| Q113936919 | Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC |
| Q113923126 | Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer |
| Q113893882 | Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma |
| Q113911750 | Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC |
| Q113938489 | Sirolimus DEB in Coronary Bifurcation Lesions |
| Q113909508 | Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer |
| Q113909415 | Study of AZD2811 + Durvalumab in ES-SCLC |
| Q113892027 | Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma |
| Q113944571 | Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients |
| Q113885243 | Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer |
| Q113918395 | Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) |
| Q113936881 | Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma |
| Q113895389 | Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
| Q113916072 | Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer |
| Q113913173 | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion |
| Q113929928 | Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma |
| Q113918885 | Study of M7824 and Paclitaxel Combination as a Second-line Treatment in Patients With Recurrent/Metastatic Gastric Cancer |
| Q113914054 | Study of Magrolimab Combinations in Participants With Myeloid Malignancies |
| Q113945609 | Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer |
| Q113929121 | Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC |
| Q113914451 | Study of ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID) |
| Q113909474 | Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer |
| Q113914084 | Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors. |
| Q113939002 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) |
| Q113899130 | Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC |
| Q113942711 | Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung |
| Q113937220 | Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) |
| Q113939036 | Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study) |
| Q113945575 | Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer |
| Q113897291 | Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases |
| Q113917453 | Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
| Q113889266 | Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer |
| Q113909794 | Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy |
| Q113916333 | Study to Evaluate Monotherapy Compared to Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer |
| Q113911421 | Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
| Q113943969 | Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy |
| Q113898991 | Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer |
| Q113925953 | Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer |
| Q113887477 | T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial |
| Q113928513 | TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
| Q113888110 | TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer |
| Q113931671 | TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer |
| Q113915938 | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients |
| Q113915236 | Tamoxifen Versus Etoposide After First Recurrence in GBM Patients |
| Q113909887 | Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma |
| Q113898997 | Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma |
| Q113894482 | Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer |
| Q113943545 | Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma |
| Q113891822 | Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines |
| Q113920721 | Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer |
| Q113913035 | Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer |
| Q113943197 | Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma |
| Q113916061 | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial |
| Q113889527 | Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults |
| Q113940649 | Tetrandrine in the Treatment of Rheumatoid Arthritis |
| Q113944404 | The DETECT Project |
| Q113913432 | The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer |
| Q113939132 | The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma |
| Q113896008 | The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer |
| Q113898202 | The Transformation of Locally Advanced Pancreatic Cancer. |
| Q113887637 | Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). |
| Q113916281 | Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable |
| Q113929052 | Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases |
| Q113940592 | Tislelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy for ESCC |
| Q113918338 | Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer |
| Q113898045 | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer |
| Q113941512 | To Evaluate Efficacy and Safety of TT-00420 as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors |
| Q113886698 | Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma |
| Q113912598 | Toripalimab Combined With Chemotherapy in Primary Tracheal Squamous Cell Carcinoma |
| Q113912650 | Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma |
| Q113928025 | Trastuzumab + ALpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) |
| Q113916632 | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) |
| Q113894840 | Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma |
| Q113909370 | Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer |
| Q113930184 | Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. |
| Q113938660 | Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax |
| Q113940969 | Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients |
| Q113890022 | Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer |
| Q113923750 | Tumor Treating Fields Therapy in Combination With Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax |
| Q113893435 | Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study |
| Q113921147 | Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer |
| Q113940618 | Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA |
| Q113937986 | Use of Drug-Coated Balloon to Improve Recanalization of a Coronary Chronic Total Occlusion After Failed Angioplasty |
| Q113929430 | Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor |
| Q113941181 | Venetoclax Basket Trial for High Risk Hematologic Malignancies |
| Q113929344 | Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia |
| Q113929442 | Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors |
| Q63319485 | Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers |
| Q113927395 | Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma |
| Q113912481 | Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL |
| Q113910670 | Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma |
| Q45150618 | A Cytotoxic and Antifungal 1,4-Naphthoquinone and Related Compounds from a New Zealand Brown Alga, Landsburgia quercifolia |
| Q26801149 | A Review of Paclitaxel and Novel Formulations Including Those Suitable for Use in Dogs |
| Q28068089 | A Review on the Terpenes from Genus Vitex |
| Q76981914 | A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer. |
| Q63838934 | A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective |
| Q24633680 | A comprehensive review on pharmacotherapeutics of herbal bioenhancers |
| Q33744498 | A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck |
| Q35549014 | African flora has the potential to fight multidrug resistance of cancer |
| Q26798674 | Albumin-bound paclitaxel in solid tumors: clinical development and future directions |
| Q34434941 | Allicin: chemistry and biological properties. |
| Q60915784 | An Overview on the Anticancer Activity of (Neem) in Gynecological Cancers |
| Q61807237 | An Update on the Effects of Glyceollins on Human Health: Possible Anticancer Effects and Underlying Mechanisms |
| Q28385065 | An evidence-based update on the pharmacological activities and possible molecular targets of Lycium barbarum polysaccharides |
| Q39260448 | Angelica keiskei, an emerging medicinal herb with various bioactive constituents and biological activities |
| Q50034004 | Anti-Cancer Activities of Diterpenoids Derived from Euphorbia fischeriana Steud |
| Q58111871 | Anti-Cancerous Potential of Polyphenol-Loaded Polymeric Nanotherapeutics |
| Q91808029 | Anti-Infective and Anti-Cancer Properties of the Annona Species: Their Ethnomedicinal Uses, Alkaloid Diversity, and Pharmacological Activities |
| Q26864994 | Anti-tumor action of trichosanthin, a type 1 ribosome-inactivating protein, employed in traditional Chinese medicine: a mini review |
| Q67929716 | Anti-tumor effect of Cetraria laevigata Rassad. polysaccharides |
| Q66925132 | Anti-tumour activity of the methanol extract Ervatamia heyneana (NSC B668619) |
| Q64889831 | Anticancer Activity and Underlying Mechanism of Phytochemicals against Multiple Myeloma. |
| Q28074711 | Anticancer Effects of Rosemary (Rosmarinus officinalis L.) Extract and Rosemary Extract Polyphenols |
| Q71086194 | Anticancer Indole Alkaloids of Rhazya stricta |
| Q92354319 | Anticancer Plants: A Review of the Active Phytochemicals, Applications in Animal Models, and Regulatory Aspects |
| Q39623942 | Antineoplastic Agents from Plants |
| Q58095598 | Antiproliferative Effects of Alkaloid Evodiamine and Its Derivatives |
| Q71046172 | Antitumor Agents. 49. Tricin,Kaempferol-3-0-β-D-Glucopyranoside and (+)-Nortrachelogenin, Antileukemic Principles From Wikstroemia indica |
| Q41690987 | Antitumor Agents: Structure-Activity Relationships in Tenulin Series |
| Q61799892 | Antitumor Effect of Various Phytochemicals on Diverse Types of Thyroid Cancers |
| Q59101356 | Antitumor activity of monoterpenes found in essential oils |
| Q44939311 | Antitumor activity of shikonin and its derivatives |
| Q70867821 | Antitumor activity of shikonin, alkannin and their derivatives. II. X-ray analysis of cyclo-alkannin leucoacetate, tautomerism of alkannin and cyclo-alkannin and antitumor activity of alkannin derivatives |
| Q70978409 | Antitumor agents XLII: Comparison of Antileukemic Activity of Helenalin, Brusatol, and Bruceantin and their Esters on Different Strains of p-388 Lymphocytic Leukemic Cells |
| Q71068258 | Antitumor agents. 44. Bis(helenalinyl) esters and related derivatives as novel potent antileukemic agents |
| Q47549627 | Apoptosis: A Target for Anticancer Therapy |
| Q42948298 | Apoptotic Effects of Polyprenylated Benzoylphloroglucinol Derivatives from the Twigs of Garcinia multiflora |
| Q26770108 | Application of Bioactive Quercetin in Oncotherapy: From Nutrition to Nanomedicine |
| Q64331398 | Benefit of Adjuvant Traditional Herbal Medicine With Chemotherapy for Resectable Gastric Cancer |
| Q37935557 | Berberine hydrochloride: anticancer activity and nanoparticulate delivery system |
| Q38242945 | Berberine, an epiphany against cancer. |
| Q88811263 | Bioactivities of Phenolics by Focusing on Suppression of Chronic Diseases: A Review |
| Q55021760 | Biological Activities of Stilbenoids. |
| Q67469029 | Biological effects of cesalin, an anti-tumor protein, on cultured mammalian cells |
| Q35155718 | Biological profile of erucin: a new promising anticancer agent from cruciferous vegetables |
| Q27002903 | Broad targeting of angiogenesis for cancer prevention and therapy |
| Q39383463 | Cancer Chemoprevention by Resveratrol: The p53 Tumor Suppressor Protein as a Promising Molecular Target. |
| Q93080654 | Capsaicin: Effects on the Pathogenesis of Hepatocellular Carcinoma |
| Q26740561 | Capsaicin: From Plants to a Cancer-Suppressing Agent |
| Q44322670 | Cesalin--an anti-neoplastic protein |
| Q37696110 | Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans |
| Q52677341 | Chemical and Biological Significance of Oenothein B and Related Ellagitannin Oligomers with Macrocyclic Structure. |
| Q37585058 | Chemical and biological characterization of oleanane triterpenoids from soy. |
| Q34465581 | Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds |
| Q54987090 | Chinese Medicines in the Treatment of Prostate Cancer: From Formulas to Extracts and Compounds. |
| Q64245399 | Chrysophanol: A Natural Anthraquinone with Multifaceted Biotherapeutic Potential |
| Q33432355 | Clinical Outcomes for Systemic Corticosteroids Versus Vincristine in Treating Kaposiform Hemangioendothelioma and Tufted Angioma |
| Q41839933 | Comprehensive review on betulin as a potent anticancer agent. |
| Q26738714 | Curcumin AntiCancer Studies in Pancreatic Cancer |
| Q90567935 | Curcumin and Cancer |
| Q26765493 | Curcumin and Health |
| Q91693060 | Curcumin and Its Derivatives as Potential Therapeutic Agents in Prostate, Colon and Breast Cancers |
| Q64251915 | Curcumin: New Insights into an Ancient Ingredient against Cancer |
| Q42715927 | Current perspectives on camptothecins in cancer treatment |
| Q67829962 | Cytotoxic Clerodane Diterpenes fromPolyalthia longifolia |
| Q92990977 | Cytotoxic Effects of Diterpenoid Alkaloids Against Human Cancer Cells |
| Q41691185 | Cytotoxic Saponins from the Chinese Herbal Drug Yunnan Bai Yao |
| Q68399787 | Cytotoxic and antitumoral activity of Calendula officinalis extracts |
| Q41031288 | Cytotoxicity of Modified Indole Alkaloids |
| Q71015422 | Cytotoxicity of siphonoside and of aliphatic esters of siphonodin (author's transl) |
| Q37096500 | Design, synthesis and applications of hyaluronic acid-paclitaxel bioconjugates. |
| Q26765440 | Dietary Natural Products for Prevention and Treatment of Liver Cancer |
| Q26782111 | Discovery of Compound A--a selective activator of the glucocorticoid receptor with anti-inflammatory and anti-cancer activity |
| Q35056376 | Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck |
| Q35602177 | Docetaxel: an alternative taxane in ovarian cancer |
| Q28072731 | Effect of Tea Polyphenol Compounds on Anticancer Drugs in Terms of Anti-Tumor Activity, Toxicology, and Pharmacokinetics |
| Q39794973 | Effect of thaliblastine on transplantable tumours in mice |
| Q26778024 | Effects of Flavonoids from Food and Dietary Supplements on Glial and Glioblastoma Multiforme Cells |
| Q60945538 | Emerging Actions of Pterostilebene on Cancer Research |
| Q39139241 | Emerging Cytotoxic Alkaloids in the Battle against Cancer: Overview of Molecular Mechanisms. |
| Q28072336 | Emerging Phytochemicals for the Prevention and Treatment of Head and Neck Cancer |
| Q26999288 | Enabling anticancer therapeutics by nanoparticle carriers: the delivery of Paclitaxel |
| Q90333840 | Enhancing Breast Cancer Treatment Using a Combination of Cannabidiol and Gold Nanoparticles for Photodynamic Therapy |
| Q26746909 | Epigallocatechin Gallate Nanodelivery Systems for Cancer Therapy |
| Q92422065 | Euphorbia-Derived Natural Products with Potential for Use in Health Maintenance |
| Q52591421 | Evaluation of efficacy and safety for Brucea javanica oil emulsion in the control of the malignant pleural effusions via thoracic perfusion. |
| Q26739934 | Evidence to Support the Anti-Cancer Effect of Olive Leaf Extract and Future Directions |
| Q37496490 | Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa |
| Q59807385 | Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid |
| Q91812151 | Fluctuations of Histone Chemical Modifications in Breast, Prostate, and Colorectal Cancer: An Implication of Phytochemicals as Defenders of Chromatin Equilibrium |
| Q40620064 | Formosan medicinal herb, Hedyotis diffusa Willd, as an antitumor agent |
| Q27021858 | Fucoidan and cancer: a multifunctional molecule with anti-tumor potential |
| Q95512489 | Hemophagocytic syndrome associated to a Hodgkin lymphoma |
| Q27003397 | Hinokinin, an emerging bioactive lignan |
| Q34279429 | Homolog of tocopherol C methyltransferases catalyzes N methylation in anticancer alkaloid biosynthesis |
| Q68314381 | House Subcommittee Scrutinizes Taxol Agreements |
| Q64093584 | Hybrid -stilbene Molecules: Novel Anticancer Agents |
| Q89098982 | Impact of taxanes on androgen receptor signaling |
| Q93048585 | In Search of Panacea-Review of Recent Studies Concerning Nature-Derived Anticancer Agents |
| Q35628160 | Induction of cancer cell death by isoflavone: the role of multiple signaling pathways |
| Q53573972 | Inhibition of spontaneous hepatocarcinogenesis in C3H/HeN mice by Edi Pro A, an isolated soy protein |
| Q55496231 | Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer. |
| Q64250550 | Isolation and Potential Biological Applications of Haloaryl Secondary Metabolites from Macroalgae |
| Q93081698 | Kaempferol: A Key Emphasis to Its Anticancer Potential |
| Q26773408 | Killing cancer with platycodin D through multiple mechanisms |
| Q67815879 | Letter: Isosteganacin |
| Q41531940 | Liposomal curcumin and its application in cancer |
| Q42368240 | Litchi chinensis as a Functional Food and a Source of Antitumor Compounds: An Overview and a Description of Biochemical Pathways |
| Q57169924 | Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer |
| Q33630122 | Mangiferin: a natural miracle bioactive compound against lifestyle related disorders |
| Q36629939 | Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine |
| Q39783909 | Mechanism of action of cesalin, an antitumor protein |
| Q91814938 | Mechanistic Understanding of Curcumin's Therapeutic Effects in Lung Cancer |
| Q94594351 | Medicinal Plants in the Prevention and Treatment of Colon Cancer |
| Q64922991 | MicroRNA-Mediated Health-Promoting Effects of Phytochemicals. |
| Q24801341 | Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy? |
| Q89510873 | Molecular Mechanisms of the Anti-Cancer Effects of Isothiocyanates from Cruciferous Vegetables in Bladder Cancer |
| Q36403641 | Molecular mechanisms of garlic-derived allyl sulfides in the inhibition of skin cancer progression |
| Q28366706 | Molecular mechanisms underlying anti-tumor promoting activities of heat-processed Panax ginseng C.A. Meyer |
| Q26764901 | Myricetin: A Dietary Molecule with Diverse Biological Activities |
| Q41608480 | Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions |
| Q26751368 | Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan |
| Q39410995 | Natural Compounds from Herbs that can Potentially Execute as Autophagy Inducers for Cancer Therapy. |
| Q46246069 | Natural Korean Medicine Dang-Gui: Biosynthesis, Effective Extraction and Formulations of Major Active Pyranocoumarins, Their Molecular Action Mechanism in Cancer, and Other Biological Activities |
| Q26739022 | Natural Polyphenols for Prevention and Treatment of Cancer |
| Q64937338 | Natural Products and Acute Myeloid Leukemia: A Review Highlighting Mechanisms of Action. |
| Q44109275 | Novel Cytotoxic Principles of Formosan Ganoderma lucidum |
| Q52657733 | Nutraceutical or Pharmacological Potential of Moringa oleifera Lam. |
| Q44162453 | Occurrence of interferon-like antiviral & antitumor factor(s) in extracts of some indigenous plants |
| Q90193879 | Overview of the Anticancer Profile of Avenanthramides from Oat |
| Q46248252 | Oxidative Stress Modulation and ROS-Mediated Toxicity in Cancer: A Review on In Vitro Models for Plant-Derived Compounds. |
| Q92353593 | Oxoisoaporphines and Aporphines: Versatile Molecules with Anticancer Effects |
| Q66040376 | Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals |
| Q27691306 | Paclitaxel: new uses for an old drug |
| Q64694321 | Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer |
| Q55491670 | Phyto-polyphenols as potential inhibitors of breast cancer metastasis. |
| Q103003286 | Phytochemical-Based Nanomedicine for Advanced Cancer Theranostics: Perspectives on Clinical Trials to Clinical Use |
| Q91519322 | Phytochemicals in Prostate Cancer: From Bioactive Molecules to Upcoming Therapeutic Agents |
| Q35155749 | Phytochemicals in cancer prevention and therapy: truth or dare? |
| Q91444885 | Phytofabrication of Nanoparticles as Novel Drugs for Anticancer Applications |
| Q98156699 | Plant Defensins from a Structural Perspective |
| Q37603607 | Plitidepsin: design, development, and potential place in therapy |
| Q36102059 | Possible Anticancer Mechanisms of Some Costus speciosus Active Ingredients Concerning Drug Discovery. |
| Q53492232 | Potent anti-tumorigenic effect of tubeimoside 1 isolated from the bulb of Bolbostemma paniculatum (Maxim) Franquet |
| Q39906038 | Potential Anticancer Agents, XI. X-Ray Structure Determination of Acantholide [1] |
| Q48308262 | Potential Anticancer Properties of Osthol: A Comprehensive Mechanistic Review. |
| Q26800877 | Potential Effects of Pomegranate Polyphenols in Cancer Prevention and Therapy |
| Q26765497 | Potential Use of Turkish Medicinal Plants in the Treatment of Various Diseases |
| Q67334462 | Potential anticancer agents VIII. Constituents of Baliospermum montanum (Euphorbiaceae) |
| Q67794312 | Potential anticancer agents. III. Jacaranone, a novel phytoquinoid from Jacaranda caucana |
| Q33218801 | Potential for improvement of docetaxel-based chemotherapy: a pharmacological review |
| Q26741336 | Precision or Personalized Medicine for Cancer Chemotherapy: Is there a Role for Herbal Medicine |
| Q44411997 | Primary non-Hodgkin's lymphoma of the thyroid. A case report and review of the literature |
| Q55215578 | Pro-Apoptotic and Anti-Cancer Properties of Diosgenin: A Comprehensive and Critical Review. |
| Q40166340 | Pro-Inflammatory, Tumour-Promoting and Anti-Tumour Diterpenes of the Plant Families Euphorbiaceae and Thymelaeaceae |
| Q26745997 | Prodrug Strategies for Paclitaxel |
| Q64929167 | Quercetin: a natural compound for ovarian cancer treatment. |
| Q67013041 | Quinquangulin, a new naphthopyrone from Cassia quinquangulata (Leguminosae) |
| Q55209672 | Regulation of Cell Signaling Pathways and miRNAs by Resveratrol in Different Cancers. |
| Q38265625 | Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer |
| Q41651679 | Relationship of the reductive metabolism of indicine N-oxide to its antitumor activity |
| Q90945224 | Research Advances of Purple Sweet Potato Anthocyanins: Extraction, Identification, Stability, Bioactivity, Application, and Biotransformation |
| Q64672120 | Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA |
| Q92495031 | Resveratrol Action on Lipid Metabolism in Cancer |
| Q64258015 | Resveratrol as a Tumor-Suppressive Nutraceutical Modulating Tumor Microenvironment and Malignant Behaviors of Cancer |
| Q37706275 | Resveratrol oligomers for the prevention and treatment of cancers |
| Q92257455 | Rodent Models Assessing Mammary Tumor Prevention by Soy or Soy Isoflavones |
| Q27000504 | Rottlerin and cancer: novel evidence and mechanisms |
| Q27002602 | Safety of higher dosages of Viscum album L. in animals and humans--systematic review of immune changes and safety parameters |
| Q28079313 | Saponins from Chinese Medicines as Anticancer Agents |
| Q67794295 | Screening of Chilean plants for anticancer activity. I |
| Q26753000 | Screening of promising chemotherapeutic candidates from plants extracts |
| Q36126134 | Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor |
| Q66932081 | Sequiterpene lactones. Part XXV. Studies on the mode of action. The cellular and molecular basis of cytostatic action |
| Q43859747 | Sesquiterpene lactones. Part XIII. Cytotoxic activity of eupatolide and eupatoriopicrin on human and animal malignant cells in tissue culture in vitro |
| Q92702276 | Solubility and Bioavailability Enhancement of Oridonin: A Review |
| Q26741169 | Spices for Prevention and Treatment of Cancers |
| Q44255560 | Structure-Activity Relationships among In Vivo Active Germacranolides |
| Q58760963 | Structure-Based Classification and Anti-Cancer Effects of Plant Metabolites |
| Q50851284 | Studies on antitumor activities of Basidiomycetes-antitumor activity of polysaccharides and sex factors |
| Q66936455 | Studies on the structure of a new antitumor agent-hainanolide (author's transl) |
| Q66979813 | Studies on the water-soluble constituents of lichens. III. Changes in antitumor effect caused by modifications of pustulan- and lichenan-type glucans |
| Q59807366 | Sulforaphane from Cruciferous Vegetables: Recent Advances to Improve Glioblastoma Treatment |
| Q41650271 | TLX–5 Lymphoma Cells in Rapid Screening for Cytotoxicity in Brucea Extracts |
| Q36396623 | Tanshinones: sources, pharmacokinetics and anti-cancer activities |
| Q36549221 | Taxol: an important new drug in the management of epithelial ovarian cancer |
| Q90945220 | Tea and Its Components Prevent Cancer: A Review of the Redox-Related Mechanism |
| Q26749391 | Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy |
| Q90152385 | The Antitumor Efficacy of β-Elemene by Changing Tumor Inflammatory Environment and Tumor Microenvironment |
| Q43445907 | The Crystal Structure and Cytotoxicity of Goniodiol-7-monoacetate from Goniothalamus amuyon |
| Q64117388 | The Health Beneficial Properties of as Potential Functional Food |
| Q47828906 | The Molecular Mechanisms of Plant-Derived Compounds Targeting Brain Cancer. |
| Q91962742 | The Potential Use of Resveratrol for Cancer Prevention |
| Q26739983 | The Role of Natural Polyphenols in the Prevention and Treatment of Cervical Cancer-An Overview |
| Q47940580 | The Role of Resveratrol in Cancer Therapy. |
| Q112223411 | The Study of Chemical Profile and Antioxidant Properties of Poplar-Type Polish Propolis Considering Local Flora Diversity in Relation to Antibacterial and Anticancer Activities in Human Breast Cancer Cells |
| Q33623423 | The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory. |
| Q34667865 | The multifaceted role of curcumin in cancer prevention and treatment. |
| Q36927558 | The pharmacological bases of the antiangiogenic activity of paclitaxel |
| Q37895519 | The role of Tau protein in resistance to paclitaxel |
| Q26798356 | The role of taxanes in triple-negative breast cancer: literature review |
| Q26744724 | Therapeutic Effectiveness of Anticancer Phytochemicals on Cancer Stem Cells |
| Q52654072 | Therapeutic Perspectives of 8-Prenylnaringenin, a Potent Phytoestrogen from Hops. |
| Q92290762 | Therapeutic Perspectives of Molecules from Urtica dioica Extracts for Cancer Treatment |
| Q52590668 | Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways. |
| Q58544569 | Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy |
| Q43003765 | Transitory, spontaneously recovering, peripheral facial nerve palsy after vionorelbine administration |
| Q38118663 | Tubulin-interactive stilbene derivatives as anticancer agents. |
| Q67794290 | Tumor inhibitors. 114. Aloe emodin: antileukemic principle isolated from Rhamnus frangula L |
| Q53699625 | Tumor-targeting delivery of herb-based drugs with cell-penetrating/tumor-targeting peptide-modified nanocarriers. |
| Q28073155 | Unraveling the Anticancer Effect of Curcumin and Resveratrol |
| Q36470377 | Update on taxane development: new analogs and new formulations |
| Q70775091 | Valepotriates, a New Class of Cytotoxic and Antitumor Agents |
| Q37305758 | Vincristine sulfate liposomal injection for acute lymphoblastic leukemia |
| Q39063436 | Vinorelbine induced perforation of a metastatic gastric lesion |
| Q33948693 | Vinorelbine--a clinical review |
| Q92372692 | Whole Grain Consumption for the Prevention and Treatment of Breast Cancer |
| Q26766956 | Withaferin-A--A Natural Anticancer Agent with Pleitropic Mechanisms of Action |
| Q91298451 | Withania Somnifera (Ashwagandha) and Withaferin A: Potential in Integrative Oncology |
| Q53427956 | [Advances in the Research of the Regulation of Chinese Traditional Medicine Monomer and Its Derivatives on Autophagy in Non-small Cell Lung Cancer]. |
| Q35734193 | nab-Paclitaxel dose and schedule in breast cancer |
| Q28078891 | β-caryophyllene and β-caryophyllene oxide-natural compounds of anticancer and analgesic properties |
Search more.